- CH₣252.66bn
- CH₣285.31bn
- $56.33bn
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition (updated)
Swiss stocks - Factors to watch on October 19
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
China biotech's ingenuity extends to dealmaking
China biotech's ingenuity extends to dealmaking
Factbox: Major drugmakers turn to China for licensing deals
Atrium Therapeutics rallies after $50 mln equity raise
US FDA expands use of Novartis drug for chronic skin condition
Brief: Novartis Says FDA Approves Rhapsido (Remibrutinib) As First Treatment For Symptomatic Dermographism
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Factbox: Global healthcare companies invest billions to boost US presence
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen (updated)
Novartis strikes about $7.8 billion mRNA deal with China's Abogen
Brief: Abogen Announces Licensing And Option Agreement With Novartis
Swiss stocks - Factors to watch on September 24
Novartis defeats drug-purchaser lawsuit over delay of Entresto generics